3Dicon presents its business strategy and developments

3DIcon Corporation (OTCBB: TDCP), the developer of groundbreaking three-dimension projection and display technologies, today provided a status report and announced several significant steps it is pursuing as a part of its business plan.

3DIcon believes that its technology has a place in the leading edge of the growth of the 3D industry. In a snapshot:

The company continues to work to access the potential of CSpace®, with the current focus on completing the development of a larger, more responsive, higher resolution image space. To that end, we are in discussions with and plan to submit a proposal to a Department of Energy national laboratory in October for their assistance in combining their extensive work in image materials with our efforts.

We have been specifically focused on the medical imaging industry for the past several months, with key meetings being held with a Midwestern medical imaging foundation for a collaborative effort in development of three-dimensional displays for use in surgical arenas, evaluation and patient education for CSpace, and exploratory discussions with a company in the business of converting 2D data to 3D in the medical field.

Our continuing research efforts have led us to a possible shortcut in the effort to develop a three-dimensional display for commercialization. This path would utilize materials and methodologies different from our current CSpace project, and funds are being sought and will be appropriated specifically for its evaluation and development. If proven, it could lead to a working 3D display in substantially less time than originally anticipated.

While the capital markets have been very difficult for all companies seeking growth financing, our efforts to fund the company and our research continue. Our current financing partner, Golden State Investors, has recently agreed to increase its funding efforts, and the company continues to evaluate other means of financing, such as grants. The company recently increased its authorized shares to facilitate financing discussions. The company recognizes shareholder concerns about dilution and will act prudently in its fund-raising efforts.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how antimicrobial exposure affects Parkinson’s disease risk